pp-193 Solution for infusion

Indication: Paroxysmal nocturnal haemoglobinuria (PNH); multiple complement-mediated disorders Clinical stage: Phase 2 — ongoing in PNH and additional complement diseases Modality: Biological (first-in-class complement factor B inhibitor — monoclonal antibody) Mechanism / Target: First-in-class inhibitor of complement factor B (fB); blocks the alternative complement pathway at an early amplification step without disrupting the classical or lectin pathways; prevents haemolysis and thrombotic complications in PNH Route / form: IV infusion / subcutaneous injection Differentiation: First-in-class complement factor B inhibitor; highly selective for the alternative pathway (preserves immune defence against pathogens dependent on classical/lectin pathways); broad applicability across complement-mediated diseases;